Cancer最新文献

{"title":"The 2021 US Preventive Services Task Force lung cancer screening eligibility criteria disproportionately exclude younger Black patients with lung cancer","authors":"Alexandra L. Potter BS,&nbsp;Sangkavi Kuhan BS,&nbsp;Priyanka Senthil BA,&nbsp;Arian Mansur BA,&nbsp;Chinmay Haridas MBBS,&nbsp;Deepti Srinivasan BS,&nbsp;Arvind Kumar MD,&nbsp;Wei Zheng MD, PhD, MPH,&nbsp;Erica T. Warner ScD, MPH,&nbsp;Chi-Fu Jeffrey Yang MD","doi":"10.1002/cncr.35676","DOIUrl":"10.1002/cncr.35676","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The 2021 US Preventive Services Task Force (USPSTF) lung cancer screening guideline may continue to exclude many younger Black individuals who have not yet accumulated enough smoking pack-years to be eligible for screening. The objective of this study was to evaluate the proportions of Black and White patients with lung cancer, stratified by age at diagnosis, who would have been eligible for lung cancer screening.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Incident lung cancer cases among Black and White individuals aged 50–80 years with a smoking history in the Southern Community Cohort Study (SCCS) were identified for analysis. The proportions of Black and White individuals, stratified by age at diagnosis, who would have qualified for screening under the 2013 and 2021 USPSTF guidelines were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1856 individuals met inclusion criteria. Compared to the 2013 USPSTF guideline, the 2021 USPSTF guideline significantly increased the proportions of Black and White patients with lung cancer who would have qualified for screening in all age groups evaluated. However, under the 2021 USPSTF guideline, there remained a notable racial disparity in lung cancer screening eligibility, particularly among younger patients with lung cancer. Only 47.4% and 61.9% of Black patients aged 50–54 and 50–59 years, respectively, would have qualified for screening under the 2021 USPSTF guideline compared to 80.3% and 88.8% of White patients aged 50–54 and 50–59 years, respectively. With increasing age, the racial disparity in lung cancer screening eligibility between Black and White patients with lung cancer was reduced, and there were no longer any statistically significant differences in screening eligibility between Black and White patients with lung cancer aged 70–74 and 75–80 years. Of Black individuals aged 50–54 and 55–59 years who were ineligible for screening, 100% and 97.5% were ineligible because they had smoked fewer than 20 pack-years, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This analysis of SCCS participants with lung cancer found that the 2021 USPSTF eligibility criteria disproportionately exclude many younger Black individuals with lung cancer, primarily because they have too few smoking pack-years.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142805663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Top advances of the year: Breast cancer","authors":"Clara R. Farley MD, FACS,&nbsp;Elizabeth Sakach MD,&nbsp;Natalie Ridge DO, MS,&nbsp;Ruth Sacks MD, MSCR,&nbsp;Kevin Kalinsky MD, MS, FASCO","doi":"10.1002/cncr.35669","DOIUrl":"10.1002/cncr.35669","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142798860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence rates of soft tissue sarcoma among U.S. military servicemen: Comparison with the rates in the general U.S. population","authors":"Julie A. Bytnar DrPH,&nbsp;Ashley B. Anderson MD,&nbsp;Benjamin K. Potter MD,&nbsp;Craig D. Shriver MD,&nbsp;Kangmin Zhu MD, PhD","doi":"10.1002/cncr.35607","DOIUrl":"10.1002/cncr.35607","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Soft tissue sarcoma (STS) is one of the most frequently diagnosed cancers among men younger than age 30 years and a leading cause of cancer death in men younger than age 40 years. The military may be more exposed to STS risk factors and have generally better health and health care access than the general population, which may relate to lower cancer risk and/or early detection. This study compared STS incidence between servicemen and men in the general U.S. population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were from the Department of Defense’s Automated Central Tumor Registry (ACTUR) and the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. Subjects were active-duty servicemen in ACTUR and men in SEER aged 18–59 years diagnosed with STS from 1990 to 2013. Age-adjusted rates, incidence rate ratios (IRR), and 95% CIs were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>STS incidence rates were lower in ACTUR than SEER overall (IRR = 0.86 [0.78-0.93]), for 18- to 39-year-old men (IRR = 0.78 [0.70-0.86]), by race (White: IRR = 0.85 [0.77-0.95]; Black: IRR = 0.77 [0.63-0.94]), for sites other than skin/connective/soft tissue (IRR = 0.49 [0.37-0.63]), other specified histologies (IRR = 0.84 [0.71-0.98]), and unspecified histology (IRR = 0.57 [0.38-0.82]). Rates were lower in ACTUR for regional (IRR = 0.37 [0.28-0.47]) and distant metastases (IRR = 0.58 [0.43-0.76]), even when race and age stratified. However, rates were higher in ACTUR for 40- to 59-year-old men (IRR = 1.25 [1.04-1.48]) and localized tumors (IRR = 1.16 [1.04-1.29]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Lower STS rates among servicemen may relate to better health and early detection and treatment of STS-associated conditions within the military health system, which provides universal care. Higher rates among 40- to 59-year-old servicemen may result from greater cumulative military-related exposures.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of a couple-based intervention addressing sexual concerns for breast cancer survivors: Results of a randomized controlled trial","authors":"Jennifer Barsky Reese PhD,&nbsp;Stephen J. Lepore PhD,&nbsp;Kristen A. Sorice BA,&nbsp;Lauren A. Zimmaro PhD,&nbsp;Jill Hasler PhD,&nbsp;Elizabeth Handorf PhD,&nbsp;Mary B. Daly MD, PhD,&nbsp;Alexandra K. Zaleta PhD,&nbsp;Kelly Westbrook MD,&nbsp;Laura S. Porter PhD","doi":"10.1002/cncr.35685","DOIUrl":"10.1002/cncr.35685","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Sexual concerns are common and problematic for breast cancer survivors. Partner and relationship factors often play a key role in determining survivors' sexual adjustment, making it likely that couple-based interventions that integrate survivors' partners could be especially promising for addressing survivors' sexual concerns. Yet few such interventions have been tested. The objective of this study was to evaluate the efficacy of the Intimacy Enhancement (IE) intervention, a four-session, couple-based intervention addressing breast cancer survivors' sexual concerns by telephone in a randomized controlled trial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Female posttreatment breast cancer survivors reporting sexual concerns and their intimate partners (<i>N</i> = 120 couples; 240 participants) were randomized either to the IE intervention or to Living Healthy Together (LHT), an active control intervention of equivalent length. Outcomes (measured at baseline, postintervention, and at 3 and 6 months postintervention) included breast cancer survivors' sexual function (primary), partners' sexual function (secondary), and survivors' and partners' psychosocial and relationship outcomes (secondary). Mixed linear regression models examined intervention effects on outcomes at all follow-ups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Model-based estimates of intervention effects showed greater improvements in survivors' overall sexual function, sexual satisfaction, arousal, lubrication, and orgasm at postintervention (<i>p</i> &lt; .05). Effects on survivors' 3-month and 6-month sexual functioning or other secondary outcomes were minimal. Most couples completed all IE sessions (97%) and LHT (92%), and satisfaction ratings were high.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Compared with an active control intervention, the IE intervention had significant short-term benefits for survivors' sexual function. Efforts may be needed to increase the longevity of the positive effects, such as more frequent or adjunctive treatments.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142790567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational study","authors":"Iona Campo Le Brun MD,&nbsp;Séphane Dalle MD, PhD,&nbsp;Laurent Mortier MD, PhD,&nbsp;Olivier Dereure MD, PhD,&nbsp;Sophie Dalac Rat MD,&nbsp;Caroline Dutriaux MD,&nbsp;Marie-Thérèse Leccia MD, PhD,&nbsp;Delphine Legoupil MD,&nbsp;Henri Montaudié MD, PhD,&nbsp;Julie De Quatrebarbes MD,&nbsp;Caroline Gaudy-Marqueste MD, PhD,&nbsp;Eve Maubec MD, PhD,&nbsp;Philippe Saiag MD, PhD,&nbsp;Cécile Pagès MD,&nbsp;Florence Brunet Possenti MD, PhD,&nbsp;Florence Granel-Brocard MD,&nbsp;Raphaël Porcher MD, PhD,&nbsp;Wendy Lefevre MSc,&nbsp;Célèste Lebbé MD, PhD,&nbsp;Emmanuelle Kempf MD, PhD","doi":"10.1002/cncr.35679","DOIUrl":"10.1002/cncr.35679","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Nivolumab obtained approval in advanced melanoma (AM) with weight-adjusted dose (WAD) administration (3 mg/kg/2 weeks). In 2018, the dosage regimen was changed to flat dose (FD) administration (240 mg/2 weeks or 480 mg/4 weeks) based on a modeling study, without clinical data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>AM patients have been prospectively included in the French national multicenter MelBase database since 2013. First-line patients treated with nivolumab monotherapy were included in the WAD or FD groups of this study. The primary end point was the incidence of grade ≥3 immune-related adverse events (irAEs). Secondary end points were incidence of any grade irAEs, and overall survival (OS) and progression-free survival (PFS). Inverse probability of treatment weighting was used to balance groups on their baseline characteristics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Between 2015 and 2022, 348 patients were included: 160 in the WAD and 188 in the FD groups. In the FD group, 45% and 27% of patients weighed &lt;75 kg and &gt;85 kg, respectively. Grade ≥3 and any grade irAEs rates were 13.1% versus 11.7% (<i>p</i> = .8) and 63.1% versus 67.0% (<i>p</i> = .5) in the WAD and FD groups, respectively. After weighting, median PFS was 3.1 and 3.7 months (hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.65–1.07), and median OS was 24.8 and 37.0 months (HR, 0.74; 95% CI, 0.54–1.01) in the WAD and FD groups, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>There was no difference in the incidence of severe irAEs and in median PFS between AM patients treated by WAD or FD nivolumab. The median OS between patient groups did not reach statistical significance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142790570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A genome-wide association study identifies eight loci associated with intraductal papillary mucinous neoplasm progression toward malignancy","authors":"Manuel Gentiluomo PhD,&nbsp;Chiara Corradi PhD,&nbsp;Laura Apadula MS,&nbsp;Annalisa Comandatore MD,&nbsp;Gaetano Lauri MD,&nbsp;Gemma Rossi MD,&nbsp;Giulia Peduzzi PhD,&nbsp;Stefano Crippa MD, PhD,&nbsp;Cosmeri Rizzato PhD,&nbsp;Massimo Falconi MD, PhD,&nbsp;Paolo Giorgio Arcidiacono MD PhD,&nbsp;Luca Morelli MD, PhD,&nbsp;Gabriele Capurso MD, PhD,&nbsp;Daniele Campa PhD","doi":"10.1002/cncr.35678","DOIUrl":"10.1002/cncr.35678","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Intraductal papillary mucinous neoplasms (IPMNs) are precursors to pancreatic cancer, but not all IPMNs progress to cancer. The objective of this study was to identify the germline genetic variants associated with IPMN clinical progression by conducting the first genome-wide association study (GWAS) and computing a polygenic hazard score (PHS) in 338 patients with IPMN.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study population was divided into two subsets, and a Cox analysis adjusted for sex, age, cyst size at diagnosis, and the top 10 principal components was performed. A PHS was calculated using the genotypes of common variants associated with IPMN progression identified.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eight loci with significant associations (<i>p</i> &lt; 5 × 10⁻⁸) were identified, and the most significant was 7q21.11-rs117620617 (hazard ratio, 16.35; 95% confidence interval, 6.93–38.60; <i>p</i> = 1.80 × 10⁻¹⁰). All variants were associated with inflammatory processes, suggesting that alleles that predispose to an inflammatory prone phenotype may promote progression. The PHS indicated a statistically significant association (hazard ratio, 18.05; 95% confidence interval, 7.96–45.80; <i>p</i> = 6.18 × 10⁻¹¹) with IPMN progression among individuals who had the highest number of effect alleles (fourth quartile) compared with those who had the lowest number (first quartile).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The current results study advance the understanding of individual predisposition to IPMN progression and underscore the potential use of genetics in the stratification of patients who have IPMN.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142783476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biochemical response to neoadjuvant androgen deprivation therapy before radiation therapy and the risk of death in patients with unfavorable-risk prostate cancer: A secondary analysis of a randomized clinical trial","authors":"Mutlay Sayan MD,&nbsp;Ming-Hui Chen PhD,&nbsp;Jing Wu PhD,&nbsp;Jonathan E. Leeman MD,&nbsp;Shalini Moningi MD,&nbsp;Martin T. King MD,&nbsp;Peter F. Orio DO,&nbsp;Paul L. Nguyen MD,&nbsp;Anthony V. D’Amico MD, PhD","doi":"10.1002/cncr.35674","DOIUrl":"10.1002/cncr.35674","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>A prostate-specific antigen (PSA) level &gt;0.5 ng/mL after 9 to 10 weeks of neoadjuvant androgen deprivation therapy and before radiation therapy (RT) was associated with an increased PSA-failure risk; however, the impact on all-cause mortality (ACM) risk after adjusting for serum testosterone level remains unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>From 2005 to 2015, 350 patients with localized, unfavorable-risk prostate cancer (PC) were randomly assigned to receive androgen deprivation therapy and RT plus docetaxel vs standard of care (SOC) with androgen deprivation therapy and RT. Multivariable Cox regression analyses were used to assess whether a significant association existed between PSA (continuous and categorized as ≤0.5 vs &gt; 0.5 ng/mL) measured at 9 to 10 weeks after randomization and ACM risk, adjusting for known PC prognostic factors and baseline testosterone level.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After a median follow-up of 10.23 years (interquartile range: 8.07–11.41), 85 patients died (25.30%), 41 from PC (48.24%). PSA level at 9 to 10 weeks after randomization was significantly associated with increased risk of ACM when analyzed as a continuous (adjusted hazard ratio, 1.16; 95% CI, 1.04–1.30; <i>p</i> = .008) or categorical covariate (&gt;0.5 vs ≤ 0.5 ng/mL; adjusted hazard ratio, 1.88; 95% CI, 1.12–3.17; <i>p</i> = .02) after adjusting for covariates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study validates that a PSA level &gt;0.5 ng/mL after neoadjuvant androgen deprivation therapy and before RT is prognostic and significantly associated with an increased ACM risk. Patients achieving this endpoint should be considered for enrollment in future randomized trials evaluating the impact of treatment escalation on ACM using a prerandomization stratification by age or validated comorbidity metrics.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142778697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dr V. Craig Jordan, PhD, DSc, FAACR","authors":"Debra A. Tonetti PhD,&nbsp;Clodia Osipo PhD,&nbsp;Ruth M. O’Regan MD, MSc","doi":"10.1002/cncr.35643","DOIUrl":"10.1002/cncr.35643","url":null,"abstract":"&lt;p&gt;Dr V. Craig Jordan, PhD, DSc, FAACR, the “Father of Tamoxifen,” passed away on June 9, 2024, at 76 years of age (Figure 1).&lt;/p&gt;&lt;p&gt;Born in Texas, Dr Jordan grew up in England. He earned doctorates in chemistry and science from the University of Leeds. During this time, he started working with ICI Pharmaceuticals (now AstraZeneca) on ICI 46474, the blockbuster drug tamoxifen. Initially developed as a contraceptive, ICI 46474 was actually found to enhance fertility. Dr Jordan was the first to note its efficacy against breast cancer, and he spent 2 years at the Worcester Foundation for Experimental Biology in Massachusetts evaluating tamoxifen as a potential treatment for breast cancer. He then returned to Leeds as a lecturer in pharmacology. After a year at the Ludwig Institute in Bern, Switzerland, he joined the faculty at the University of Wisconsin–Madison. In 1993, he was recruited to Northwestern University as professor of cancer pharmacology and director of the Breast Cancer Research Program at the Robert H. Lurie Comprehensive Cancer Center. During his time at Northwestern, he was appointed as the inaugural Diana, Princess of Wales Professor of Cancer Research and led a successful breast cancer Specialized Program of Research Excellence (SPORE) grant. In 2005, he joined the Fox Chase Cancer Center as the Alfred G. Knudson Chair of Cancer Research, and in 2009 moved to Georgetown University as professor of oncology and pharmacology and scientific director of the Lombardi Comprehensive Cancer Center. In 2014, he moved back to Texas as professor of medical oncology and molecular and cellular oncology at the MD Anderson Cancer Center.&lt;/p&gt;&lt;p&gt;Dr Jordan’s considerable contributions to breast cancer have significantly affected the lives of many thousands of women with breast cancer and have been recognized by multiple awards, including the Medal of Honor for Basic Research from the American Cancer Society, the Charles F. Kettering Prize from the General Motors Cancer Research Foundation, and the American Society of Clinical Oncology David A. Karnofsky Award. He was elected a member of the National Academy of Sciences and the National Academy of Medicine. In 2002, Queen Elizabeth II made him an officer of the Order of the British Empire, and a companion of the Order of St. Michael and St. George in 2019.&lt;/p&gt;&lt;p&gt;One of Dr Jordan’s greatest strengths was his ability to build teams that remain intact even through today. We were all closely mentored by Dr Jordan, and we took what we learned and applied it to one another. As an example, Dr O’Regan joined the Jordan team during her fellowship, with absolutely zero laboratory experience. Dr Jordan linked her up with Dr Tonetti, who painlessly mentored her on basic laboratory experiments throughout her time at Northwestern. He was an expert in training the mentee to become a mentor. All three of us spent our early careers as part of the Jordan “Tamoxifen Team,” and each of us is now a tenured professor at o","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35643","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142764722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy recommendation, initiation, and completion: Complex questions of access and equity","authors":"Edward Christopher Dee MD,&nbsp;Erin Jay G. Feliciano MD, MBA,&nbsp;Nina N. Sanford MD,&nbsp;Puneeth Iyengar MD PhD","doi":"10.1002/cncr.35654","DOIUrl":"10.1002/cncr.35654","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142764733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024","authors":"Alan H. Bryce MD,&nbsp;Neeraj Agarwal MD,&nbsp;Himisha Beltran MD,&nbsp;Maha H. Hussain MD,&nbsp;Oliver Sartor MD,&nbsp;Neal Shore MD,&nbsp;Emmanuel S. Antonarakis MD,&nbsp;Andrew J. Armstrong MD, MSc,&nbsp;Jeremie Calais MD, PhD,&nbsp;Michael A. Carducci MD,&nbsp;Tanya Barauskas Dorff MD,&nbsp;Jason A. Efstathiou MD, DPhil,&nbsp;Martin Gleave MD,&nbsp;Leonard G. Gomella MD,&nbsp;Celestia Higano MD,&nbsp;Thomas A. Hope MD,&nbsp;Andrei Iagaru MD,&nbsp;Alicia K. Morgans MD, MPH,&nbsp;David S. Morris MD,&nbsp;Michael J. Morris MD,&nbsp;Daniel P. Petrylak MD,&nbsp;Robert E. Reiter MD,&nbsp;Matthew B. Rettig MD, MBA,&nbsp;Charles J. Ryan MD,&nbsp;Scott B. Sellinger MD,&nbsp;Daniel E. Spratt MD,&nbsp;Sandy Srinivas MD,&nbsp;Scott T. Tagawa MD, MS,&nbsp;Mary-Ellen Taplin MD,&nbsp;Evan Y. Yu MD,&nbsp;Tian Zhang MD,&nbsp;Rana R. McKay MD,&nbsp;Phillip J. Koo MD,&nbsp;E. David Crawford MD","doi":"10.1002/cncr.35612","DOIUrl":"10.1002/cncr.35612","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142764730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}